Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and advanced HER2-positive solid tumours, which have driven sales to more than $3. ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

Meanwhile, AZ and Daiichi just launched the four-arm phase 3 Destiny-Gastric05 trial to test Enhertu as a first-line treatment for HER2-positive stomach cancer. The study currently bears a primary ...

Doctors prescribe Enhertu for certain types of breast, lung, and other cancers in ... In brief, the cancers are: HER2-positive breast cancer unresectable or metastatic HER2-low breast cancer ...

ENHERTU is designed as a monotherapy for adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low or HER2 ultralow breast cancer who have previously undergone at ...

ENHERTU is designed as a monotherapy for adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low or HER2 ultralow breast cancer who have previously ... Interstitial ...

The recommendation, announced today, specifically targets adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have previously ...